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NON-TOXIC GOITER 
PETER C. SCRIBA 
K l i n i k für Innere Medizin, Medical U n i v e r s i t y of Lübeck, Ratze-
burger A l l e e 160, D 2400 Lübeck (FRG) 
ETIOLOGY 
Obviously the e t i o l o g y of non-toxic goiter i s heterogeneous. 
While iodine d e f i c i e n c y i s the predominant cause (1, 8), there 
are other reasons for sporadic and endemic goiter, as goitrogens 
from water and food supplies (2, 5), goitrogenic drugs, and i n -
born defects of thyroid hormone synthesis and metabolism. In ad-
d i t i o n , t h y r o i d growth stimulating Immunoglobulin may play a 
r o l e , though some of the observations could have been due to con-
tamination (4) e. g. with EGF (epidermal growth f a c t o r ) . 
EPIDEMIOLOGY 
Non-toxic goi t e r remains a major health problem (1), wherever 
iodine d e f i c i e n c y p r e v a i l s as an endemic problem. Recent reports 
show the worldwide d i s t r i b u t i o n of iodine deficiency, with sev-
e r a l hundred m i l l i o n people l i v i n g at the r i s k of goiter (8). 
Non-toxic goiter, however, represents only the most obvious exam-
ple of the whole spectrum of iodine d e f i c i e n c y disorders, which 
includes retarded growth, mental d i s a b i l i t y etc. In general i t 
may be said, that most epidemiological data are poor and do not 
comply with recommendations by PAHO (14). For instance, d e f i n i -
t i o n by stages i s not r e g u l a r l y applied i n studies published. 
A better quantization of thyroid s i z e can be achieved by 
ultrasonography even i n epidemiological f i e l d studies (7, 16). 
This procedure has an average error of 10 to 15 °r, and permitted 
to demonstrate e. g. the frequency d i s t r i b u t i o n of thyroid volume 
in Sweden, where iodine intake s u f f i c e s , as compared to the Fed-
e r a l Republic of Germany, where almost half of the c h i l d r e n have 
enlarged thyroids (7). In addition, ultrasound patterns cf the 
thyroid were abnormal i n only 3.6 % of the Swedish adult Popula-
t i o n as compared to 16 % i n Germany. 
1434 
IODINE PROPHYLAXIS 
The e r a d i c a t i o n of iodine d e f i c i e n c y c a r r i e s important ef-
fects on the q u a l i t y of l i f e , the p r o d u c t i v i t y and e d u c a b i l i t y of 
those affected as summarized by the ICCIDB (8). The global pre-
vention of t h i s c o n d i t i o n has been advocated by the UN and the 
WHO. Once i n s t a l l e d , the maintenance of iodine prophylactic pro-
grams has to be continucusly monitored. 
The ETA has reported (14), that the s u f f i c i e n t iodine intake 
in Northern European countries i s l a r g e l y inadvertently, and for 
instance due to the use of iodophors as desinf ectants. Only few 
countries l i k e Czechoslovakia and Switzerland use adequately 
iodized s a l t . In other parts of the world, i o d i z e d o i l given e i -
ther intramuscularly or c r a l l y i s used for Prophylaxis (1, 8). We 
have experience with some 12 000 i n j e c t i o n s of iodized o i l i n 
Tanzania, and could not confirm the increase of thyroid antibod-
ies as claimed by others (16). 
DIAGNOSIS IN THE INDIVIDUAL : NON-TOXIC GOITER 
Non-toxic g o i t e r remains a condition, which can only be 
diagnosed af t e r exclusion of other thyroid disorders. Even i n 
countries with a well funded health System, we have to define a 
r a t i o n a l diagnostic strategy (13) i n order to l i m i t the ever i n -
creasing expenses. In Table I, the simple determination of the 
TABLE I 
Exclusion of Rational procedure +) 
Hypothyroidism 
Thyrotoxicosis 
basal TSH (MCA) 











Nodular a l t e r a t i o n s i n c l . 
Thyroid Malignancy 
Ultrasonography 
FNA - Cytology 
+) NB: Sometimes more, sometimes less may be needed 
German Society f o r Endocrinology - Thyroid Section (13) 
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basal TSH with a highly s e n s i t i v e radioimmunoassay i s recommended 
as the f i r s t and sole procedure to exclude hypothyroidism and/or 
t h y r o t o x i c o s i s . Notably, non-toxic g o i t e r i s defined as a 
condition where the patient i s euthyroid and free from 
t h y r o i d i t i s or thyroid malignancy. Autonomy i s excluded by 
scintigraphy. Sonography has become the dominating f i r s t hand 
procedure to diagnose t h y r o i d i t i s and t h y r o i d malignancy and i s 
used for c o n t r o l l e d f i n e needle a s p i r a t i o n (FNA) cytology. 
THERAPY 
As generally agreed, non-toxic g o i t e r may be treated by 
surgery. There i s also a place f o r the a p p l i c a t i o n of radioiodine 
(3) i n the treatment of non-toxic g o i t e r ; c e r t a i n l y t h i s kind of 
treatment represents a p r i v i l e g e of the somewhat luxurious 
medicine of countries with a high l i v i n g Standard. Patients aged 
60 or older may p r o f i t most, though the reduction i n thyroid s i z e 
i s only l i m i t e d . Few i f any of these p a t i e n t s need a thyroid 
hormone replacement therapy a f t e r r a d i o i o d i n e . 
There i s cu r r e n t l y a controversy going on, whether to treat 
young non-toxic goi t e r patients with thyroxine or iodine (9). As 
a t h e o r e t i c a l background, the debate continues, whether TSH i s a 
d i r e c t growth stimulator of the t h y r o i d . I f t h i s would be 
correct, TSH suppressive thyroxine doses should be the l o g i c a l 
therapy for non-toxic go i t e r . Other authors consider growth 
factors (EGF) and the iodine content of the thy r o i d c e l l i t s e l f 
as important for p r o l i f e r a t i o n and h y p e r p l a s i a of the thy r o i d 
gland (15). 
Obviously, there are non-toxic g o i t e r s with firm nodules which 
do not respond to medication (6). The optimal patient for medical 
treatment would rather be a young p a t i e n t up to 25 years old with 
a d i f f u s e g o i t e r of recent onset (11). More than 80 % of these 
patients respond favorably to the treatment. Using Sonographie 
volumetry as an i d e a l means of C o n t r o l l i n g the e f f e c t , i t was 
shown, that s i z e reduetions by 30 - 35 % are to be expected, when 
thyroxine i s given for a period of 3 to 6 months (12). 
Thereafter, no further decrease of t h y r o i d s i z e can be achieved. 
Stopping thyroxine w i l l lead to g o i t e r relapse within a few 
weeks. S u r p r i s i n g l y , the relapse i s slower, when iodine i s 
applied to reduce g o i t e r (9, 12). A f t e r s u c c e s s f u l medical ther-
apy, one has to enter a mean of Prophylaxis to prevent recurrence 
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of g o i t e r by either administering half the amount of the i n i t i a l 
thyroxine dose or by 100 to 200 ug iodine/d. What was s a i d i s 
true for endemic g o i t e r i n an iodine d e f i c i e n c y area. There are 
no convincing data on conservative therapy of goiters due to 
other causes. 
As convincingly shown i n ch i l d r e n (10), treatment with 
iodine alone can also decrease goiter si z e by 30 - 40 %. The 
recommendation to treat adults from 25 to 40 or even 50 years of 
age with iodine i s less c l e a r , waiting for further studies (9). 
Treatment of patients with goiter by eit h e r thyroxine of iodine 
i s not very l i k e l y to be successful a f t e r approximately 40 to 50 
years of age. In patients older than t h i s , one has tc consider 
e i t h e r surgery or radioiodine or may i n other cases just observe 
the patient. 
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